You are viewing: France AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The France AI in Life Science Market was valued at $776.4 Million in 2026 and projected to reach to $2547.8 Million by 2031, representing a compound annual growth rate of 26.8%. France's AI in Life Science market is poised for exceptional growth, driven by substantial government initiatives, robust healthcare infrastructure, and increasing collaboration between academic institutions and pharmaceutical companies.

France AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 26.8%, reflecting France's strategic investments in healthcare innovation and digital transformation.
  • France is positioning itself as a key hub for AI-driven life science applications across drug discovery, diagnostics, and personalized medicine. The French market benefits from strong government support, a well-established pharmaceutical sector, and growing adoption of AI technologies among research institutions and healthcare providers.
  • Between 2026 and 2031, France is expected to see accelerated integration of machine learning and artificial intelligence across clinical workflows and biotech research.
  • This growth trajectory underscores France's commitment to leveraging AI to enhance healthcare outcomes and maintain competitive advantage in the European life science landscape..

Key Market Statistics

  • CAGR (2026-2031) 26.8% CAGR
  • Market Size, 2026 ~USD 776.4 Million
  • Forecast, 2031 ~USD 2547.8 Million
  • Country France

France AI in Life Science Market Overview

Strong Market Valuation :

France's AI in Life Science market is valued at $776.4 million in 2026, demonstrating significant investment in healthcare innovation and digital transformation across the country.

Exceptional Growth Trajectory :

With a CAGR of 26.8% from 2026 to 2031, France's market growth outpaces the global average of 26.3%, indicating accelerated adoption of AI technologies in life sciences.

Projected Market Expansion :

The market is forecasted to reach $2,547.8 million by 2031, representing a 228% increase over five years and positioning France as a major European hub for AI-driven life science solutions.

Strategic Healthcare Innovation Hub :

France is leveraging government support and private sector investments to establish itself as a key center for AI applications in drug discovery, diagnostics, and personalized medicine.

France AI in Life Science Market Dynamics

  • The country's commitment to digital health transformation and innovation funding creates a favorable environment for AI adoption across drug discovery, clinical diagnostics, and patient management systems. The projected expansion to $2,547.8 million by 2031 reflects France's strategic positioning as a European leader in AI-driven life sciences.
  • Key growth drivers include regulatory support for digital health solutions, rising demand for personalized medicine, and significant R&D investments from both public and private sectors.
  • France's strong pharmaceutical heritage combined with emerging AI capabilities positions it for sustained market leadership..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • France's AI in Life Science market will grow from $776.4M (2026) to $2,547.8M (2031) at a 26.8% CAGR.
    • France is leveraging government support and pharmaceutical expertise to drive AI adoption in healthcare and biotech.
    • France's market growth outpaces the global average, positioning the country as a European leader in AI life science innovation.
    • Between 2026 and 2031, France will see significant expansion in AI applications for drug discovery, diagnostics, and personalized medicine.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    France AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    FRANCE: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES35.343.955.670.889.2113.3143.1178.726.3
    BIOTECHNOLOGY COMPANIES113.4141.7180.7231.7293.7375.8477.7600.527.1
    CRO & CDMO79.198.4124.8159.1200.6255.2322.7403.426.4
    DIAGNOSTIC COMPANIES43.35468.788111.3142.1180.3226.226.9
    OTHER END USERS24.730.638.749.261.878.398.6122.725.9
    PHARMACEUTICAL COMPANIES193.6241.7307.8394.2499637.6809.61016.327
    TOTAL489.5610.4776.49931255.41602.22031.92547.826.8

    Target Audience

    • Pharmaceutical & Biotech Companies : French and international pharma firms need market intelligence to identify AI investment opportunities, assess competitive positioning, and develop localized strategies for drug discovery and development.
    • Healthcare Technology Investors : Venture capital and private equity firms require detailed market data to evaluate investment potential in French AI life science startups and identify high-growth opportunities in the region.
    • Medical Device & Diagnostics Manufacturers : Companies developing AI-powered diagnostic and medical devices need France-specific market insights to understand demand, regulatory pathways, and commercialization strategies.
    • Healthcare Policy & Government Bodies : French health authorities and policy makers require market analysis to inform digital health initiatives, funding decisions, and regulatory frameworks supporting AI innovation in life sciences.
    • Research & Academic Institutions : Universities and research centers need market data to guide AI life science research priorities, identify collaboration opportunities, and understand commercialization potential in France.

    Key Companies in the France AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise valuation metrics for France's AI in Life Science market with detailed CAGR analysis, enabling accurate financial forecasting and investment planning specific to the French market.
    • Competitive Landscape Intelligence : Understand France's market positioning relative to global trends, identify local competitors, and recognize opportunities in Europe's fastest-growing AI life science ecosystem.
    • Strategic Investment Guidance : Make informed decisions on market entry, expansion, or partnership strategies in France with comprehensive data on growth drivers, regulatory environment, and sector-specific opportunities.
    • Sector-Specific Insights : Gain detailed understanding of AI applications across French drug discovery, diagnostics, and personalized medicine segments to align product development and go-to-market strategies.
    • Risk & Opportunity Assessment : Evaluate market dynamics, identify emerging trends, and assess competitive threats specific to France's healthcare AI landscape for strategic planning and resource allocation.

    Frequently asked questions

    What is the current size of France's AI in Life Science market?

    France's AI in Life Science market is valued at $776.4 million in 2026 and is projected to grow to $2,547.8 million by 2031.

    What is the growth rate for AI in Life Science in France?

    France's AI in Life Science market is growing at a compound annual growth rate (CAGR) of 26.8% from 2026 to 2031.

    What are the main drivers of AI adoption in France's life science sector?

    France's AI adoption is driven by government support for healthcare innovation, a strong pharmaceutical industry base, and increasing integration of AI in drug discovery, diagnostics, and personalized medicine applications.

    How does France's AI in Life Science market compare to global trends?

    France's market growth rate of 26.8% CAGR exceeds the global average of 26.3%, demonstrating France's accelerated adoption and investment in AI life science technologies.

    Which applications are driving growth in France's AI in Life Science market?

    Key applications include AI-powered drug discovery, clinical diagnostics, personalized medicine, and biomarker identification across France's research institutions and healthcare providers.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status